Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

This study has been terminated.
(PI left the institution)
Information provided by (Responsible Party):
Loma Linda University Identifier:
First received: February 11, 2010
Last updated: May 28, 2014
Last verified: May 2014

Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.

Kidney Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy

Resource links provided by NLM:

Further study details as provided by Loma Linda University:

Primary Outcome Measures:
  • LAK cytotoxicity [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: November 2009
Study Completion Date: March 2012
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
patients with melanoma or kidney cancer

Detailed Description:

Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic dehydrogenase release from lysed cells.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center


Inclusion Criteria:

  • Patients must be undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center
  • Patients must sign and give written informed consent in accordance with institutional and federal guidelines

Exclusion Criteria:

  • Patients not undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01068470

United States, California
Loma Linda University Cancer Center
Beaumont, California, United States, 92223
Sponsors and Collaborators
Loma Linda University
Principal Investigator: Walter Quan, MD Loma Linda University
  More Information

No publications provided

Responsible Party: Loma Linda University Identifier: NCT01068470     History of Changes
Other Study ID Numbers: 59210
Study First Received: February 11, 2010
Last Updated: May 28, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Loma Linda University:
Kidney Cancer
Lymphokine Activated Killer cells

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Kidney Neoplasms
Kidney Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Analgesics, Non-Narcotic
Antineoplastic Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 25, 2014